FDA Approves Blueprint Medicines' Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

Article Link: FDA Approves Blueprint Medicines’ Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

First precision therapy that specifically targets the primary driver of the disease
Durable clinical responses, including complete remissions, shown in patients with or without prior treatment
Full approval supported by robust efficacy and…

Source: FDA New Drug Approvals